Move to topTop
April 25, 2013

Tokyo - Terumo Corporation (TSE: 4543 Section 1) announced that it has signed a co-development agreement for PTA balloon catheters with Kaneka Corporation (TSE: 4118 Section 1). Under the terms of the agreement, both companies will conduct product development. In addition, Kaneka will manufacturer and Terumo will then market the product across the globe. Commencing the sales in the U.S. market in fiscal 2014 and subsequently expanding the sales area and product portfolio, Terumo aims to achieve the revenue of 2.5 billion yen in fiscal 2016.

PTA (Percutaneous Transluminal Angioplasty)

Peripheral artery disease is associated with a blocked artery in the leg mainly caused by atherosclerosis. PTA is a procedure in which a small balloon at the end of thin catheter is inflated to restore blood flow. Since PTA is a minimally invasive therapy for the treatment of patients with peripheral artery disease, its application is expected to further expand worldwide.

Objectives of the co-development agreement

In 2011, Terumo concluded an OEM agreement with Kaneka Corporation for its PTA balloon catheter, Senri™ (currently marketed in Europe and Japan). Meanwhile, the co-development agreement at this time is not limited to one product but extends to a broad array of PTA balloon catheters varying for different applications and lesions. Kaneka Corporation is a top manufacturer of PTA balloon catheters in Japan with its high technology and product quality. On the other hand, Terumo has already introduced its peripheral stent Misago™ in Europe and Japan, in addition to its global sales of guide wires and introducer sheaths. By additionally expanding its PTA balloon catheter lineup, Terumo aims to further develop its business in peripheral vascular intervention.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.